Research progress on the regulation of the Wnt/β-catenin signaling pathway by LncRNAs in bladder cancer
10.3969/j.issn.1009-8291.2025.09.014
- VernacularTitle:膀胱癌中长链非编码RNA对Wnt/β-catenin信号通路调控的研究进展
- Author:
Rui LI
1
;
Fei WANG
1
;
Weifu WANG
1
Author Information
1. 海南省人民医院,海南医科大学附属海南医院泌尿外科,海南海口 570311
- Publication Type:Journal Article
- Keywords:
bladder cancer;
long non-coding RNA;
Wnt/β-catenin;
signaling pathway;
targeted therapy
- From:
Journal of Modern Urology
2025;30(9):803-807
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer has a complex pathogenesis involving the dysregulation of multiple signaling pathways.The malignant progression of bladder cancer is closely associated with the aberrant activation of the Wnt/β-catenin signaling pathway,which is regulated by long non-coding RNAs(LncRNAs)at multiple levels,affecting tumor proliferation,metastasis,and drug resistance.LncRNAs regulate the Wnt/β-catenin pathway through three main mechanisms.Firstly,β-catenin stability,where SNHG7 inhibits GSK3β-mediated degradation,promoting nuclear accumulation of β-catenin,whereas GAS5 enhances its degradation via the miR-18a-5p/AXIN2 axis.Secondly,regulation of downstream target genes,with oncogenic LncRNAs such as CASC9 and PVT1 activating cyclin D1 and MMPs through miRNA sponging,driving epithelial-mesenchymal transition(EMT)and invasion,while the tumor-suppressive LncRNAs miR143HG inhibits β-catenin nuclear translocation.Thirdly,crosstalk with other signaling pathways,as exemplified by CARLo-7,which simultaneously activates both the Wnt/β-catenin and JAK2/STAT3 pathways,exacerbating the malignant phenotype.As potential biomarkers and therapeutic targets,LncRNAs have demonstrated promising potential in preclinical models.This review summarizes the key LncRNAs involved in bladder cancer and their mechanisms in regulating the Wnt/β-catenin pathway,providing new insights for the precise treatment of bladder cancer.
